Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 25
---
 be unable to complete the development of our product candidates.                       |

| • | Our operations are in early-stage development with no sources of recurring revenue and there is no assurance 
 that we will successfully develop and license our product candidates or ever become profitable.              |

| • | We are exposed to political, regulatory, social and economic risk relating to the United Kingdom’s 
 exit from the European Union.                                                                      |

| • | We have undertaken in the past, and may in the future undertake, strategic acquisitions. Failure to integrate 
 acquisitions could adversely affect our value.                                                                |

| • | Our future success is dependent on product development and the ability to successfully license our product 
 candidates to partners who can seek regulatory approval and commercialization of our product candidates.   |

| • | Our development efforts are in the early stages. All of our product candidates are in clinical development                                  
 or preclinical development phases. If we are unable to advance our product candidates through clinical development, obtain regulatory       
 approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially 
 harmed.                                                                                                                                     |

| • | The results of preclinical studies and early clinical trials are not always predictive of future results.                               
 Any product candidate that we advance in clinical trials may not achieve favorable results in later clinical trials, if any, or receive 
 marketing approval.                                                                                                                     |

| • | The regulatory approval processes in the United States and Europe are lengthy, time consuming and inherently                               
 unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may be substantially 
 harmed.                                                                                                                                    |

| • | We seek to establish agreements with potential licensing partners and collaborators and, if we are not                     
 able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. |

| 13 |

| • | If we enter into agreements with a licensing or collaboration partner for the development and commercialization                           
 of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those 
 collaborations.                                                                                                                           |

| • | The commercial success of any of our product candidates is not guaranteed. |

| • | The pharmaceutical and biotechnology industries are highly competitive. |

| • | Changes in healthcare policies, laws and regulations, including legislative measures aimed at reducing health care costs, may impact 
 our ability to obtain approval for or commercialize any of our future product candidates, if approved.                               |

| • | Coverage and adequate reimbursement may not be